2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Stampacchia Otello | Director | 6,737,023 | Sep 18, 2019 |
| Omega Fund V, L.P. | 10% Owner | 6,553,416 | Sep 23, 2019 |
| Omega Fund V GP, L.P. | 10% Owner | 6,553,416 | Sep 23, 2019 |
| Omega Fund V GP Manager, Ltd. | 10% Owner | 6,553,416 | Sep 23, 2019 |
| Hasnain Faheem | CEO | 5,408,073 | Oct 2, 2025 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Jan 5, 2026 | Hasnain Faheem | CEO | Neutral | 82.5 | +280,000 | 4.69% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Giraudo Bryan | CFO | Neutral | 90.0 | +115,750 | 15.35% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Smith Robert Paul JR | Chief Commercial Officer | Neutral | 90.0 | +93,750 | 48.79% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Aranda Richard | Chief Medical Officer | Neutral | 90.0 | +93,750 | 25.21% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 90.0 | +84,500 | 48.33% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 90.0 | +84,500 | 10.59% | ✗ | - |
| Oct 1, 2025 | Oct 2, 2025 | Smith Robert Paul JR | Chief Commercial Officer | Neutral | 90.0 | +162,500 | 650.00% | ✗ | - |
| Oct 1, 2025 | Oct 2, 2025 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 90.0 | +125,000 | 19.11% | ✗ | - |
| Oct 1, 2025 | Oct 2, 2025 | Giraudo Bryan | CFO | Neutral | 90.0 | +181,250 | 31.65% | ✗ | - |
| Oct 1, 2025 | Oct 2, 2025 | Aranda Richard | Chief Medical Officer | Neutral | 90.0 | +162,500 | 77.60% | ✗ | - |
| Oct 1, 2025 | Oct 2, 2025 | Hasnain Faheem | CEO | Neutral | 85.0 | +437,500 | 7.91% | ✗ | - |
| Oct 1, 2025 | Oct 2, 2025 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 90.0 | +125,000 | 250.84% | ✗ | - |
| Aug 19, 2025 | Aug 20, 2025 | Milligan Sandra | Director | Buy | 95.0 | +26,050 | 81.41% | ✗ | $50K |
| Jun 25, 2025 | Jun 26, 2025 | Daniel Thomas O | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2025 | Jun 26, 2025 | Nathan Steven D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2025 | Jun 26, 2025 | Cox Russell J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2025 | Jun 26, 2025 | Quisel John D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2025 | Jun 26, 2025 | Milligan Sandra | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 25, 2025 | Jun 26, 2025 | Drynan Skye | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 4, 2025 | Mar 6, 2025 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 4, 2025 | Mar 6, 2025 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 4, 2025 | Mar 6, 2025 | Smith Robert Paul JR | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 4, 2025 | Mar 6, 2025 | Aranda Richard | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 4, 2025 | Mar 6, 2025 | Giraudo Bryan | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 4, 2025 | Mar 6, 2025 | Hasnain Faheem | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 24, 2024 | Jun 25, 2024 | Aranda Richard | Chief Medical Officer | Sell | 50.0 | -1,908 | -0.95% | ✗ | $1.3K |
| Jun 21, 2024 | Jun 24, 2024 | Hasnain Faheem | CEO | Buy | 92.5 | +372,000 | 7.21% | ✗ | $250.3K |
| Jun 18, 2024 | Jun 20, 2024 | Giraudo Bryan | CFO | Buy | 95.0 | +100,000 | 26.32% | ✗ | $59.1K |
| Jun 17, 2024 | Jun 20, 2024 | Smith Robert Paul JR | Chief Commercial Officer | Buy | 91.3 | +25,000 | 100.00% | ✗ | $15.1K |
| Jun 6, 2024 | Jun 6, 2024 | Quisel John D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2024 | Jun 6, 2024 | Milligan Sandra | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2024 | Jun 6, 2024 | Cox Russell J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 6, 2024 | Jun 6, 2024 | Daniel Thomas O | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 27, 2024 | Mar 28, 2024 | Christian Waage | EVP, Tech Ops and Admin | Sell | 50.0 | -6,430 | -0.97% | ✗ | $7.4K |
| Mar 27, 2024 | Mar 28, 2024 | Giraudo Bryan | CFO | Sell | 47.5 | -6,430 | -1.34% | ✗ | $7.4K |
| Mar 27, 2024 | Mar 28, 2024 | Hasnain Faheem | CEO | Sell | 51.3 | -23,172 | -0.45% | ✗ | $26.8K |
| Mar 18, 2024 | Mar 19, 2024 | Aranda Richard | Chief Medical Officer | Sell | 47.5 | -4,018 | -1.98% | ✗ | $5.3K |
| Mar 18, 2024 | Mar 19, 2024 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 47.5 | -4,018 | -7.46% | ✗ | $5.3K |
| Mar 11, 2024 | Mar 12, 2024 | Drynan Skye | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 11, 2024 | Mar 12, 2024 | Nathan Steven D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 12, 2024 | Drynan Skye | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 12, 2024 | Nathan Steven D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 2, 2024 | Jan 4, 2024 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2024 | Jan 4, 2024 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2024 | Jan 4, 2024 | Aranda Richard | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2024 | Jan 4, 2024 | Giraudo Bryan | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2024 | Jan 4, 2024 | Hasnain Faheem | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 4, 2023 | Dec 5, 2023 | Smith Robert Paul JR | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 5, 2023 | Smith Robert Paul JR | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Nov 28, 2023 | Nov 29, 2023 | Quisel John D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 29, 2023 | Quisel John D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Nov 20, 2023 | Nov 22, 2023 | Aranda Richard | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | Giraudo Bryan | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | Hasnain Faheem | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 20, 2023 | Nov 22, 2023 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Nov 15, 2023 | Nov 17, 2023 | Milligan Sandra | Director | Buy | 91.3 | +32,000 | 100.00% | ✗ | $25.2K |
| Nov 13, 2023 | Nov 14, 2023 | Giraudo Bryan | CFO | Buy | 95.0 | +200,000 | 71.64% | ✗ | $112.9K |
| Jul 24, 2023 | Jul 26, 2023 | Giraudo Bryan | CFO | Neutral | 90.0 | +54,020 | 27.51% | ✗ | - |
| Jul 24, 2023 | Jul 26, 2023 | Hasnain Faheem | CEO | Neutral | 90.0 | +540,176 | 11.64% | ✗ | - |
| Jul 24, 2023 | Jul 26, 2023 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 77.5 | +13,504 | 2.12% | ✗ | - |
| Jun 22, 2023 | Jun 26, 2023 | Aranda Richard | Chief Medical Officer | Sell | 50.0 | -1,814 | -0.90% | ✗ | $2.3K |
| Jun 8, 2023 | Jun 9, 2023 | GALA RENEE D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 9, 2023 | Cox Russell J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 9, 2023 | Milligan Sandra | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 9, 2023 | Daniel Thomas O | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 8, 2023 | Jun 9, 2023 | Burow Kristina | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 5, 2023 | May 9, 2023 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 5, 2023 | May 9, 2023 | Aranda Richard | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 5, 2023 | May 9, 2023 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 5, 2023 | May 9, 2023 | Giraudo Bryan | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| May 5, 2023 | May 9, 2023 | Hasnain Faheem | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 4, 2023 | Apr 5, 2023 | Giraudo Bryan | CFO | Buy | 95.0 | +55,000 | 32.32% | ✗ | $56.1K |
| Mar 20, 2023 | Mar 22, 2023 | Carter Laura | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 20, 2023 | Mar 22, 2023 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 20, 2023 | Mar 22, 2023 | Aranda Richard | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Mar 20, 2023 | Mar 22, 2023 | Christian Waage | EVP, Tech Ops and Admin | Buy | 83.8 | +18,500 | 2.99% | ✗ | $22.1K |
| Mar 20, 2023 | Mar 22, 2023 | Giraudo Bryan | CFO | Buy | 91.3 | +50,000 | 41.61% | ✗ | $48.4K |
| Mar 20, 2023 | Mar 22, 2023 | Hasnain Faheem | CEO | Buy | 100.0 | +878,572 | 23.36% | ✗ | $1M |
| Mar 16, 2023 | Mar 20, 2023 | Carter Laura | Chief Scientific Officer | Sell | 47.5 | -6,029 | -7.33% | ✗ | $6.6K |
| Mar 16, 2023 | Mar 20, 2023 | Aranda Richard | Chief Medical Officer | Sell | 47.5 | -7,563 | -3.61% | ✗ | $8.3K |
| Mar 16, 2023 | Mar 20, 2023 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 47.5 | -7,564 | -12.32% | ✗ | $8.3K |
| Dec 7, 2022 | Dec 9, 2022 | Carter Laura | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 7, 2022 | Dec 9, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 7, 2022 | Dec 9, 2022 | Aranda Richard | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 7, 2022 | Dec 9, 2022 | Christian Waage | EVP, Tech Ops and Admin | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 7, 2022 | Dec 9, 2022 | Giraudo Bryan | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Dec 7, 2022 | Dec 9, 2022 | Hasnain Faheem | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Oct 24, 2022 | Oct 27, 2022 | Carter Laura | Chief Scientific Officer | Sell | 42.5 | -4,876 | -5.59% | ✗ | $58.9K |
| Oct 24, 2022 | Oct 25, 2022 | Peterson Caryn | EVP, Regulatory Affairs | Sell | 42.5 | -4,757 | -7.19% | ✗ | $57.4K |
| Oct 24, 2022 | Oct 25, 2022 | Carter Laura | Chief Scientific Officer | Sell | 42.5 | -4,876 | -5.59% | ✗ | $58.9K |
| Oct 24, 2022 | Oct 25, 2022 | Aranda Richard | Chief Medical Officer | Sell | 42.5 | -4,757 | -2.24% | ✗ | $57.4K |
| Jun 9, 2022 | Jul 15, 2022 | Burow Kristina | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 9, 2022 | Jul 15, 2022 | Daniel Thomas O | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 9, 2022 | Jul 15, 2022 | Cox Russell J. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 9, 2022 | Jul 15, 2022 | Bilenker Joshua H. | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 9, 2022 | Jul 15, 2022 | Milligan Sandra | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jun 9, 2022 | Jul 15, 2022 | GALA RENEE D | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jul 15, 2022 | Jul 15, 2022 | Carter Laura | Chief Scientific Officer | Buy | 86.3 | +6,934 | 8.64% | ✗ | $50K |
| Jul 15, 2022 | Jul 15, 2022 | Christian Waage | EVP, Tech Ops and Admin | Buy | 78.8 | +6,934 | 1.14% | ✗ | $50K |